Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS (FIL_BIOWM)
Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Asti, Italy, 14100
- SOS Ematologia Ospedale C. Massaia
-
Bari, Italy, 70124
- IRCCS Istituto Tumori Giovanni Paolo II - UOC Ematologia
-
Naples, Italy, 80131
- AOU Università degli Studi della Campania Luigi Vanvitelli
-
Padova, Italy, 35128
- I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1
-
Parma, Italy, 43126
- A.O. Universitaria Di Parma
-
Pavia, Italy, 27100
- Ematologia Policlinico San Matteo
-
Reggio Emilia, Italy, 42123
- AO Arcispedale Santa Maria Nuova - IRCCS
-
Rimini, Italy, 47924
- Ospedale degli Infermi di Rimini
-
Roma, Italy, 00168
- Policlinico A. Gemelli Università Cattolica del Sacro Cuore
-
Siena, Italy, 53100
- UOC Ematologia, AOU Senese
-
Torino, Italy
- A.O. Città della Salute e della Scienza Ematologia Universitaria
-
Udine, Italy, 33100
- Azienda Sanitaria Universitaria Integrata di Udine (A.S.U.I. Udine) - PO S. Maria della Misericordia
-
Varese, Italy, 21100
- Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI
-
-
MI
-
Milan, MI, Italy
- Divisione di Ematologia Ospedale Niguarda
-
-
-
-
-
Salamanca, Spain
- Hematology Department, Laboratory of Molecular Biology and HLA typing, University Hospital of Salamanca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of IgM monoclonal gammopathy of undetermined significance (Ig-MGUS) or Waldenström's Macroglobulinemia (WM) according to criteria established at the second International Workshop on Waldenström's Macroglobulinemia [1]
- Age ≥ 18 years
- Previously untreated patients (only for the prospective cohort)
- Symptomatic or asymptomatic disease
- Subject understands and voluntarily signs an informed consent form approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB)
Exclusion Criteria:
- Active HBV, HCV or HIV infection (antiHBc+ patients with undetectable HBV-DNA are eligible to the study)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patient enrolled
Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)
|
Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of mutation
Time Frame: 22 months
|
To demonstrate that the rate of mutations of MYD88 (L265P) and/or CXCR4 (S338X) detected in peripheral blood and/or urine show a negligible difference with the rate of mutations detected in bone marrow samples (BM, gold standard)
|
22 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marzia Varettoni, Pavia - IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Neoplastic Processes
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Neoplasms, Plasma Cell
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Neoplasm, Residual
- Waldenstrom Macroglobulinemia
- Cell Physiological Phenomena
- Genetic Phenomena
- Clonal Evolution
Other Study ID Numbers
Other Study ID Numbers
- FIL_BIOWM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.